Here are the 10-K annual reports from Anixa Biosciences, Inc. (ANIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIX filings page.
Anixa Biosciences, Inc. is an early-stage biotechnology company focused on oncology, developing a CAR-T cell therapy and multiple cancer vaccines rather than generating product revenue. Its lead therapeutic, lira-cel, is a follicle stimulating hormone receptor–targeted CAR-T for ovarian cancer in a Phase 1 dose-escalation trial at Moffitt Cancer Center; four dose cohorts up to 30-times the initial dose have been treated and the therapy has been described as well-tolerated with anecdotal signs of efficacy in heavily pretreated patients.
The company’s breast cancer vaccine, licensed from Cleveland Clinic and targeting α-lactalbumin, completed a 35-participant Phase 1 trial, meeting all primary endpoints and showing protocol-defined immune responses in 74% of subjects with mainly injection-site irritation as the key adverse event. Final data were presented in December 2025 and will guide planned Phase 2, including a potential Keytruda combination study. Anixa is also advancing an ovarian cancer vaccine within the NCI PREVENT program and an early discovery effort for lung, colon and prostate cancer vaccines.
Financially, as of October 31, 2025 Anixa reported an accumulated deficit of approximately $251,677,000, fiscal 2025 losses of about $11,028,000, cash, cash equivalents and short-term investments of roughly $15,174,000, and working capital of about $13,920,000. Management believes existing resources can fund operations for at least 12 months, but the company expects to continue incurring losses, remains pre-revenue in therapeutics and vaccines, and may need substantial additional capital, including under a current at-the-market equity program that permits up to $100 million of future common stock sales.